Sartorius and the European Molecular Biology Laboratory Collaborate on Training
PTSM: Pharmaceutical Technology Sourcing and Management
Sartorius and EMBL have entered into a corporate partnership program to foster advanced training.
Sartorius announced on Feb. 17, 2017 that it was partnering with the European Molecular Biology Laboratory (EMBL) research institute to advance scientific training and education. Sartorius will lend its expertise to EMBL’s Corporate Partnership Program, which fosters training collaboration to connect industry to academia.
The EMBL Corporate Partnership Program creates training courses, sponsors conferences, and organizes workshops at the institute’s International Center for Advanced Training. Sartorius will provide long-term support to EMBL’s education program by funding yearly travel bursaries for teachers who wish to attend EMBL’s Learning Laboratory for the Life Sciences classes.
“By focusing on professional training at all levels and ensuring that the next generation of young talent has access to the latest knowledge, we aim to support the scientific community to reach its maximum potential,” stated Karen Storm, vice-president of Marketing of the Lab Products & Services Division at Sartorius, in a press release.
Source: Sartorius
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
